Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients

Rezvan Rostami, Shivam Om Mittal, Reza Radmand, Bahman Jabbari, Rezvan Rostami, Shivam Om Mittal, Reza Radmand, Bahman Jabbari

Abstract

Cancer patients who undergo surgery or radiation can develop persistent focal pain at the site of radiation or surgery. Twelve patients who had surgery or radiation for local cancer and failed at least two analgesic medications for pain control were prospectively enrolled in a research protocol. Patients were injected up to 100 units of incobotulinum toxin A (IncoA) intramuscularly or subcutaneously depending on the type and location of pain (muscle cramp or neuropathic pain). Two patients passed away, one dropped out due to a skin reaction and another patient could not return for the follow up due to his poor general condition. All remaining 8 subjects (Age 31-70, 4 female) demonstrated significant improvement of Visual Analog Scale (VAS) (3 to 9 degrees, average 3.9 degrees) and reported significant satisfaction in Patients' Global Impression of Change scale (PGIC) (7 out of 8 reported the pain as much improved). Three of the 8 patients reported significant improvement of quality of life.

Keywords: Patients’ Global Impression of Change; cancer pain; incobotulinum toxin A; onabotulinum toxin A; radiation; surgery; visual analog scale.

References

    1. Hopkins K.G., Rosenzweig M. Post-thoracotomy pain syndrome: Assessment and intervention. Clin. J. Oncol. Nurs. 2012;16:365–370. doi: 10.1188/12.CJON.365-370.
    1. Terrazzino S., la Mattina P., Gambaro G., Masini L., Franco P., Canonico P.L., Genazzani A.A., Krengli M. Common variants of GSTP1, GSTA1, and TGFβ1 are associated with the risk of radiation-induced fibrosis in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2012;83:504–511. doi: 10.1016/j.ijrobp.2011.06.2012.
    1. Lee S., Thiele C. Factors associated with free flap complications after head and neck reconstruction and the molecular basis of fibrotic tissue rearrangement in preirradiated soft tissue. J. Oral Maxillofac. Surg. 2010;68:2169–2178. doi: 10.1016/j.joms.2009.08.026.
    1. Bach C.A., Wagner I., Lachiver X., Baujat B., Chabolle F. Botulinum toxin in the treatment of post- radiosurgical neck contracture in head and neck cancer: A novel approach. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2012;129:6–10. doi: 10.1016/j.anorl.2011.07.002.
    1. Schreiber K.L., Kehlet H., Belfer I., Edwards R.R. Predicting, preventing and managing persistent pain after breast cancer surgery: The importance of psychosocial factors. Pain Manag. 2014;4:445–459. doi: 10.2217/pmt.14.33.
    1. Ballantyne J.C. Chronic pain following treatment for cancer: The role of opioids. Oncologist. 2003;8:567–575. doi: 10.1634/theoncologist.8-6-567.
    1. Fleming J.A., O’Connor B.D. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res. Manag. 2009;14:381–388.
    1. Kirova Y.M., Fromantin I., de Rycke Y., Fourquet A., Morvan E., Padiglione S., Falcou M.C., Campana F., Bollet M.A. Can we decrease the skin reaction in breast cancer patients using hyaluronic acid during radiation therapy? Results of phase III randomised trial. Radiother. Oncol. 2011;100:205–209.
    1. Wittekindt C., Liu W.C., Preuss S.F., Guntinas-Lichius O. Botulinum toxin A for neuropathic pain after neck dissection: A dose-finding study. Laryngoscope. 2006;116:1168–1171. doi: 10.1097/01.mlg.0000217797.05523.75.
    1. Jabbari B. Botulinum Toxin Treatment of Pain Disorders. Springer-Verlag; New York, NY, USA: 2015.
    1. Van Daele D.J., Finnegan E.M., Rodnitzky R.L., Zhen W., McCulloch T.M., Hoffman H.T. Head and neck muscle spasm after radiotherapy: Management with botulinum toxin A injection. Arch. Otolaryngol. Head Neck Surg. 2002;128:956–959. doi: 10.1001/archotol.128.8.956.
    1. Hartl D.M., Cohen M., Juliéron M., Marandas P., Janot F., Bourhis J. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol. Head Neck Surg. 2008;138:459–463. doi: 10.1016/j.otohns.2007.12.021.
    1. Mittal S., Machado D.G., Jabbari B. OnabotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation. Pain Med. 2012;13:1029–1033. doi: 10.1111/j.1526-4637.2012.01437.x.
    1. Dessy L.A., Maruccia M., Mazzocchi M., Scuderi N. Treatment of post mastectomy pain syndrome after mastopexy with botulinum toxin. J. Plast. Reconstr. Aesthet. Surg. 2014;67:873–874. doi: 10.1016/j.bjps.2013.12.032.
    1. Terkawi A.S., Sharma S., Durieux M.E., Thammishetti S., Brenin D., Tiouririne M. Perioperative lidocaine infusion reduces the incidence of post-mastectomy chronic pain: A double-blind, placebo-controlled randomized trial. Pain Physician. 2015;18:139–146.
    1. Cregg R., Anwar S., Farquhar-Smith P. Persistent postsurgical pain. Curr. Opin. Support. Palliat. Care. 2013;7:144–252. doi: 10.1097/SPC.0b013e328360b09e.
    1. Deumens R., Steyaert A., Forget P., Schubert M., Lavand’homme P., Hermans E., de Kock M. Prevention of chronic postoperative pain: Cellular, molecular, and clinical insights for mechanism-based treatment approaches. Prog. Neurobiol. 2013;104 doi: 10.1016/j.pneurobio.2013.01.002.
    1. Kehlet H., Jensen T.S., Woolf C.J. Persistent postsurgical pain: Risk factors and prevention. Persistent postsurgical pain: Risk factors and prevention. Lancet. 2006;36:1618–1625. doi: 10.1016/S0140-6736(06)68700-X.
    1. List M.A., Bilir S.P. Functional outcomes in head and neck cancer. Semin. Radiat. Oncol. 2004;14:178–189. doi: 10.1053/j.semradonc.2003.12.008.
    1. Welch M.J., Purkiss J.R., Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–258. doi: 10.1016/S0041-0101(99)00153-1.
    1. Meng J., Ovsepian S.V., Wang J., Pickering M., Sasse A., Aoki K.R., Lawrence G.W., Dolly J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 2009;29:4981–4992. doi: 10.1523/JNEUROSCI.5490-08.2009.
    1. Shin M.C., Wakita M., Xie D.J., Yamaga T., Iwata S., Torii Y., Harakawa T., Ginnaga A., Kozaki S., Akaike N. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J. Pharmacol. Sci. 2012;118:33–42. doi: 10.1254/jphs.11060FP.
    1. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133. doi: 10.1016/j.pain.2003.10.008.
    1. Marino M.J., Terashima T., Steinauer J.J., Eddinger K.A., Yaksh T.L., Xu Q. Botulinum toxin B in the sensory afferent: Transmitter release, spinal activation, and pain behavior. Pain. 2014;155:674–684. doi: 10.1016/j.pain.2013.12.009.
    1. Bach-Rojecky L., Lacković Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 2009;94:234–238. doi: 10.1016/j.pbb.2009.08.012.
    1. Mazzocchio R., Caleo M. More than at the neuromuscular synapse: Actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015;21:44–61. doi: 10.1177/1073858414524633.
    1. Drinovac V., Bach-Rojecky L., Lacković Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J. Neural Transm. 2014;121:665–669. doi: 10.1007/s00702-013-1150-6.
    1. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology. 2001;56:1290–1293. doi: 10.1212/WNL.56.10.1290.
    1. Babcock M.S., Foster L., Pasquina P., Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: A short-term, randomized, placebo-controlled, double-blind study. Am. J. Phys. Med. Rehabil. 2005;84:649–654. doi: 10.1097/01.phm.0000176339.73591.d7.
    1. Ranoux D., Attal N., Morain F., Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 2008;64:274–283. doi: 10.1002/ana.21427.
    1. Aurora S.K., Dodick D.W., Turkel C.C., DeGryse R.E., Silberstein S.D., Lipton R.B., Diener H.C., Brin M.F. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. doi: 10.1177/0333102410364676.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться